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INTRODUCTION:
Triple negative breast cancer (TNBC) accounts for 10-15% of all breast cancer [1] and is defined by an immunohistochemical absence of expression for oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [2] . Patients with TNBC typically present with high-grade disease and often an early pattern of recurrence [1, [3] [4] [5] . With no drug-targetable receptors [6] , chemotherapy continues to be the mainstay of treatment in TNBC patients.
At present, there are no specific clinical guidelines for treating TNBC [7, 8] . Like other breast cancers, locoregional management of TNBC comprises breast conserving therapy (BCT) i.e.: breast conserving surgery followed by radiotherapy, or mastectomy (with or without adjuvant radiotherapy). While there is international consensus on indications for postmastectomy radiotherapy (PMRT) [8] [9] [10] , these guidelines do not account for breast cancer subtype.
A recent systematic review of over 12,000 patients by Lowery et al [11] examined locoregional recurrence risk after breast cancer surgery according to receptor phenotype. The authors compared TNBC patients to other non-TNBC patients and found that TNBC was associated with an increased risk of locoregional recurrence following BCT, as well as mastectomy. The findings of this study are important, as it serves to highlight that TNBC is an aggressive disease with a higher risk of local recurrence compared to other breast cancer subtypes, irrespective of the locoregional therapy. Nevertheless, this systematic review does not provide evidence on whether the surgical procedures per se, or adjuvant radiotherapy therein, have any prognostic role in TNBC. In order to address the ongoing debate of 6 whether adjuvant radiotherapy confers any recurrence-free or survival benefit in patients with TNBC [12] [13] [14] [15] [16] , there needs to be a direct comparison between various locoregional treatment strategies within patients with triple negative disease.
Previous studies examining recurrence and survival outcomes in patients with TNBC according to locoregional treatment status have produced conflicting results [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] .
It is likely that several of these studies were underpowered due to their small sample size [19] [20] [21] 30] . Moreover, potentially important survival differences may exist depending on disease stage [18, 22] and age at diagnosis [18] . We therefore conducted a meta-analysis to determine the risk of locoregional/distant recurrence, and overall survival associated with BCT or PMRT, versus mastectomy alone in patients with TNBC. Such analysis is needed for informed decision-making regarding the optimum locoregional treatment strategies in TNBCs.
METHODOLOGY:

Search strategy
This meta-analysis was conducted in accordance to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement [31] . Four electronic databases (MEDLINE, EMBASE, PubMED and Web of Science) were searched from January 2000 to November 2015. The year 2000 was chosen as a cut-off, as this is the date from which molecular subtypes of breast cancer were first defined [32] . No other date or language restrictions were imposed. The search strategy (Table 2 , online only), developed in MEDLINE, was comprised of several key search terms combined with the boolean operators AND/OR aligned to relevant medical subject headings, and included various terms for 'breast cancer', 'breast conserving therapy/mastectomy', 'triple negative' and 'survival/recurrence' outcomes.
Study eligibility
Observational studies and randomised controlled trials reporting hazard ratios (HRs), odds ratios (ORs) or relative risks (RRs) and associated 95% confidence intervals (CIs) for overall and/or locoregional/distant recurrence were included if they examined 1) breast cancer patients with triple negative (non-metastatic) disease at diagnosis who 2) clearly stratified survival/recurrence endpoints by the type of surgery (mastectomy or breast conserving therapy) received and 3) in which radiotherapy status was reported. All studies in which standardised therapy was administered were considered eligible regardless of the exact chemotherapeutic regimens (i.e.: neo-adjuvant/adjuvant) or radiotherapy protocols. A concerted effort was made to contact the authors of all potentially relevant studies to obtain effect estimates or counts of events by surgical/radiotherapy exposure status that were not reported in the original paper.
Data collection and extraction
Each electronic database was searched by the principal reviewer (MO'R). Three reviewers then indendently scanned the titles and abstracts of all identified papers after duplicate removal (MO'R, NB, LM). The full papers from all potentially relevant studies were then sourced and read. Data extraction was undertaken by two reviewers (MO'R, NB) using a pre-defined excel spreadsheet, recording detailed information on the origin of the study (country and year), characteristics of the population under study (study size, age and follow-up time, stage of disease), survival estimates and associated 95% CIs and covariates for adjustment in the analysis. The methodological quality of included cohort studies was assessed using the Newcastle-Ottawa scale [33] and the Cochrane risk of bias tool was used for assessing randomised trials [34] .
Statistical analysis
Effect estimates and associated 95% CIs comparing survival and recurrence outcomes stratified by surgical type (BCT or PMRT) were extracted from all relevant papers. Wherever possible we reported on multivariable adjusted effect estimates.
Within studies from which an unadjusted effect estimate could be derived from the raw counts of exposed and unexposed patients, corresponding effect estimates were estimated by calculating a rate ratio in Stata using the 'CSI' command. Individual study authors were also contacted to obtain frequencies not reported in the original article. One study [24] , through personal communication with the authors, provided anonymous individual patient data which enabled its inclusion in specific subgroup analysis. The principal quantitative synthesis involved a comparison of BCT and PMRT. Mastectomy only patients were used as the reference group in all analyses.
Study-specific effect estimates were pooled using a random effects model, as described by DerSimonian and Laird [35] , to account for both within-study sampling error (variance) and between-study variation. The degree of statistical heterogeniety was assessed using the Cochrane's Q test and the percentage variation in the effect estimate attributable to this heterogeniety was assessed using the I-squared statistic [36] . In post-hoc sensitivity analysis, the influence of each individual study was assessed by excluding each in turn and re-running the analyses monitoring for changes in heterogeniety and the overall summary estimate. Given the reported survival differences with adjuvant radiotherapy in more advanced disease [18, 22] and younger patients [18], planned subgroup analyses by age group (<40, 40-64, ≥65 years) and early (T1-2, N0-1) and late stage (T3-4, N2-3) disease were also undertaken. Begg's rank correlation test [37] and Egger's linear regression test [38] were conducted to investigate potential small study effects or other publication biases. Stata IC v. 11.0 (StataCorp, College Station, TX, USA) was used for all analyses.
RESULTS:
A total of 1,539 papers were identified. Of these, 1,473 were clearly irrelevant from the initial screening of their title and abstract. Upon closer inspection of the remaining 66 papers (for which the full text articles were sought), only 12 met the criteria for inclusion. Justification for subsequent study exclusions are documented in Figure 1 . Table 1 summarises the characteristics of the 12 included studies. Of these, the majority (9 out of 10) were retrospective cohort studies and two were randomised controlled trials. The methodological quality of the included cohort studies was moderate to high with a mean score of six out of a possible nine (range 4 to 8; Table   3 , online only). There appeared to be a low risk of bias in the included randomised controlled trials across all domains (Table 4 , online only); however, blinding of surgical procedure and radiotherapy receipt was not practicable in this context. The median follow-up period ranged between 1.9 to 7.2 years across the studies and locoregional recurrence was the most commonly assessed endpoint in 9 studies [17, [19] [20] [21] [22] [23] 25, 29, 30] . The median age at diagnosis ranged from 50 to 59 years with the largest study including 1,138 TNBC patients [18] , and the two smallest [19, 30] consisted of 62 TNBC patients each. In 5 studies, patients who had undergone neoadjuvant chemotherapy prior to surgery were excluded [17, 19, 25, 29, 30] . The majority of studies were conducted in the USA or Asia.
Locoregional recurrence
Six studies [17, [19] [20] [21] 29, 30] 
Distant recurrence
Five studies (1,615 patients) reported on distant recurrence [17, 19, 21, 29, 30] . The pooled HR comparing BCT to mastectomy only patients was HR 0.88 (95% CI 0.63, 1.25), Figure 3 . There was no evidence of heterogeniety. Four studies (1,059 patients) [17, 19, 21 ,23] compared PMRT to mastectomy only, the pooled HR was 1.40 (95% CI 0.63, 3.10), and significant heterogeniety was detected Pheterogeniety =0.000, I 2 = 87.6%, Figure 3 . Only one study [29] examined distant recurrence in patient's with early-stage disease. It was not possible to examine the impact of latestage disease (T3-4, N2-3) or age at diagnosis and the risk of distant recurrence by radiotherapy receipt.
Overall survival
Six studies (3,184 patients) compared BCT to mastectomy only for overall survival [17] [18] [19] 21, 24, 29] . The pooled HR was 0.57 (95% CI 0.36-0.88), Figure 4 ; moderate heterogeniety was present (Pheterogeniety =0.07, I 2 = 50.5%). There was little difference when the analysis was restricted to four studies [17, 18, 24, 29] There was no statistically significant interaction between disease stage and BCT/PMRT on overall survival, Pinteraction= 0.983. Combining data from two studies [18, 24] , the effect of age at diagnosis on overall survival comparing PMRT and BCT to mastectomy only was examined, the corresponding pooled effect estimates were HR 0.30 (95% CI 0.11-0.82) and HR 0.22 (95% CI 0.04, 1.13) age <40 years, HR 0.76 (95% CI 0.37-1.58) and HR 0.38 (95% CI 0.11, 1.31) aged 40-64 years, and HR 0.67 (95% CI 0.14-3.18) and HR 0.79 (95% CI 0.22-2.76) aged ≥65 years respectively, Figure 6 (online only). No statistically significant interaction was detected, Pinteraction =0.847.
Sensitivity analyses
For each comparison undertaken (i.e.: BCT/PMRT versus mastectomy only), in posthoc sensitivity analysis we excluded each study in turn to monitor for individual study effects on heterogeniety and the overall effect estimate. One relatively large (n=768) study of stage T1-3, N0-3 patients [17] , had a strong influence on the observed effect estimates for several of the outcomes studied. For locoregional recurrence (6 studies) comparing BCT to mastectomy only, removal of this one study [17] , resulted in a slight attenuation of the overall effect estimate HR 0.72 (95% CI 0.46, 1.15), Pheterogeniety =0.823, I 2 = 0.0%. For distant recurrence comparing PMRT to mastectomy only (4 studies), the exclusion of this same study [17] , attenuated the pooled estimate HR 0.94 (95% CI 0.58-1.52) Pheterogeniety =0.196 and explained much of the observed heterogeniety (I 2 =38.7%). For overall survival, comparing PMRT to mastectomy only (7 studies), exclusion of the study by Abdulkarim et al [17] , again attenuated the pooled effect estimate HR 0.86 (95% CI 0.72-1.02) and significantly lowered heterogeniety (I 2 = 7.6%, P=0.363). The systematic removal of other studies, including those of different study designs (i.e.: randomised trial versus cohort study) or from conference proceedings only, failed to materially alter the overall pooled effect estimates or heterogeniety (data not shown).
Publication bias
Begg and Egger tests were undertaken to assess for publication and other small study biases. There was no evidence of publication/small-study bias in comparisons where locoregional recurrence or overall survival were study outcomes (data not shown). However, in comparisons of BCT to mastectomy alone for distant recurrence (5 studies), there was some evidence of publication or other small-study bias (Begg p=0.221, Egger p=0.009). The resulting Egger regression plot showed deviation of the intercept from zero, indicating marked asymmetry with relatively few studies of higher precision.
DISCUSSION:
There is a paucity of studies that have examined the prognostic impact of adjuvant radiotherapy in breast cancer patients with triple negative disease. The findings from this study show that administration of adjuvant radiotherapy confers a locoregional recurrence-free survival benefit in TNBC, irrespective of the type of surgery initially received. The administration of adjuvant radiotherapy was not significantly associated with distant recurrence, and there was no consistent overall survival benefit observed between locoregional treatment groups.
Previous studies evaluating the value of radiotherapy in TNBC patients have shown conflicting results. A study of 768 patients from a comprehensive cancer centre in a single Canadian province, reported an increased risk of locoregional recurrence in T1-2, N0 TNBC patients treated with mastectomy only in comparison to those receiving BCT, suggesting that adjuvant radiotherapy may be an important factor in optimising local control; however there was no observed difference in overall survival [17] . Conversely, a retrospective study of 646 T1-2, N0 TNBC patients in the USA, reported no significant difference in locoregional recurrence between patients receiving BCT or mastectomy [29] . Several other studies which also included patients with more advanced cancer stages showed that BCT administration was associated with lower risk of locoregional recurrence than mastectomy alone, albeit not achieving statistical significance [20, 21, 30] . It is however likely that these studies were underpowered due to their small sample size.
A prospective, randomised controlled multi-centre study, which was conducted in the era before TNBC was recognised as a specific entity, had documented that in women with stage I or stage II TNBC undergoing mastectomy, administration of radiotherapy combined with chemotherapy, was associated with superior local recurrence-free survival compared to chemotherapy alone [27] . In a study from the Danish Breast Cancer Co-operative Group 82 b and c trials, Kyndi et al [23] examined the impact of breast cancer subtypes on PMRT response. The trial included data from 152 TNBC patients with high-risk disease (i.e.: either positive lymph nodes or T3/4 disease), 74 of which were randomised to receive PMRT. In multivariable analysis, the authors reported significantly smaller locoregional recurrence reductions in the TNBC subtype. While the authors suggested that this was perhaps a result of increased radioresistance in these tumours, these results may be explained by the higher mitotic index and aggressive clinical course of TNBCs, which may not necessarily be radioresistant [17] . Moreover, the predisposition to BRCA mutations in TNBC patients, which renders the tumour defective in DNA repair, has been argued as a mechanism for increased radiosensitivity [12] . A prospective single institutional study of 77 TNBC patients with Recently, the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted a meta-analysis of individual patient data from 22 randomised trials including over 8,000 women [39] . Whilst not specifically reporting on patients with TNBC, this study found that PMRT among women with one to three positive axillary nodes, significantly reduced not only locoregional, but also distant recurrence, even when systemic therapy was given [39] . In line with this evidence, Kyndi et al [23] using data from the Danish Breast Cancer Co-operative Group trials, reported a significant increased risk of distant recurrence among TNBC patients not receiving PMRT. However, other studies have shown non-significant increased risks of distant recurrence in patients undergoing PMRT compared to mastectomy only [17, 19, 21] .
In pooled analysis in the present study, distant recurrence was not significantly associated with either PMRT or BCT in comparison to patients recieving mastectomy only. The absence of any clear effect may be attributable to the small number of studies (low power) examining this endpoint.
In this meta-analysis, radiation therapy does not appear to be consistently associated with an overall survival benefit in TNBCs. This is in view of the fact that we only observed a higher overall survival in patients subjected to BCT compared to mastectomy only, but not in patients undergoing PMRT. Steward et al [24] conducted a retrospective investigation of 468 patients with stage I-III (T1-4, N0-3) TNBC from a single USA centre. Similar to the current findings, the authors only found a survival benefit associated with radiotherapy in women undergoing breast conservation and not in those receiving mastectomy. This observation may be partly explained by the underlying differences in patient selection for type of surgery, whereby breast conserving surgery is typically indicated for patients with smaller tumours (T1-2) [40] , and conceivably a better baseline prognosis [41] . This notion is supported by the findings of the present meta-analysis, wherein the initial survival benefit associated with BCT compared to mastectomy in all-stage patients was attenuated and nonsignificant within patients with very early stage disease (T1-2, N0 tumours).
Based on the pooled HRs from the current meta-analysis there was a suggestion of a stronger overall survival benefit associated with BCT compared to mastectomy alone in women with late-stage disease (T3-4, N2-3) and younger age at diagnosis (<40 years). However, these findings should be interpreted with caution as we found no evidence of effect modification by stage or age, perhaps owing to the small number of studies available for stratified analyses. Further prospective studies in these subgroups are warranted. Whilst the mechanism for a preferential overall survival benefit of adjuvant radiotherapy in younger patients is unknown, one potential explanation may be that the presence of underlying BRCA gene mutation in these patients may have influenced RT response [42] , as it is suggested that tumours that arise in BRCA carriers are likely to be more sensitive to the effects of ionizing radiation [43] .
A strength of the present analysis was the stratification of TNBC patients according to locoregional management (i.e.: BCT versus PMRT), as patients with a less favourable prognosis may be more likely to receive PMRT than BCT [41] , making it inappropriate to classify the BCT and PMRT as a composite adjuvant radiotherapy group. In planned subgroup analysis, we attempted to ascertain differences in response to adjuvant radiotherapy by both stage of disease and age at diagnosis.
The average follow-up time among the 12 included studies in this systematic review was 4.6 years (range 1.9-7.2), although in two studies follow-up was under 3 years [20, 21] . Accounting for other known prognostic factors, it has been previously reported that TNBCs exhibit a distinctive early pattern of recurrence, peaking at 2-3 years, with the majority occurring within the first 5 years [44] . Therefore, the followup periods in the majority of the included studies in the present review are likely adequate to determine their intended survival endpoints.
The limitations of this systematic review principally relate to the fact that it is not a meta-analysis of individual patient data and that there were only a small number of contributing studies, which were often limited by the lack of details reported in the original publication. Wherever possible, efforts were made to contact the authors of the original paper to obtain stratified frequencies of events by type of surgery and radiotherapy receipt. In all, 16 authors were contacted by e-mail for data requests. Of the 7 replies received, only 2 authors provided additional information [19, 24] . Of note, two of the studies included in the present analysis were from conference proceedings only [20, 30] and two were randomised controlled trials [23, 27] .
However, their exclusion in post-hoc sensitivity analysis did not materially alter the pooled findings. The majority of included studies were single institution, retrospective, non-randomised study designs with likely differences in the clinical and pathologic characteristics of their patient populations (Table 1) . This may have inevitably contributed to the observed high heterogeneity in certain estimates.
It is also important to note that the TNBC subtype per se, is not in itself an indication for post-mastectomy radiotherapy [45] , and that the decision to irradiate is influenced by many factors including tumour-related prognostic features (i.e.: involved margins, larger tumour size, positive lymph node status, lymphovascular invasion), patientrelated factors (i.e.: socioeconomic status, patient preference/values) and health system-related factors (physician-preference/values, availability of radiotherapy machines). Whilst some of these aspects were accounted for in the analyses of several studies included in the current meta-analysis, other factors are inherently difficult to capture and may have impacted our findings to some extent.
While it is conceivable that systemic treatment may have varied between the different settings where the studies in this review were conducted, it is felt that this may not have influenced the results to a great extent. This review addresses patients with non-metastatic triple negative breast cancer, in whom the (global) standard of care for neoadjuvant/adjuvant treatment during the study period was anthracycline +/-taxane based chemotherapy, to which TNBCs have been shown to be particularly sensitive [46] . Dose intensity may well have differed between the different study populations, particularly in Asia [47] . However, other than specifying chemotherapy regimen, this information was not available in the studies included in the current review. Only five studies reported the exclusion of patients who had undergone neoadjuvant chemotherapy prior to surgery [17, 19, 25, 29, 30] . This may be particularly important to bear in mind, as the response to neo-adjuvant treatment may differentially affect the patterns of recurrence and overall survival in TNBC patients [48] . Many included studies whilst reporting on the raw frequencies of outcomes by type of surgery and radiotherapy use, did not conduct multivariable survival analysis.
In such studies, we calculated an unadjusted risk ratio, which unfortunately leaves open the potential for confounding.
In summary, this systematic review and meta-analysis shows that adjuvant radiotheray, irrespective of the extent of initial breast surgery, is associated with locoregional recurrence benefits in patients with TNBC. However radiotherapy, was not consistently associated with an improvement in overall survival. While subgroup analyses seem to suggest that adjuvant radiotherapy may be more strongly associated with an overall survival gain in patients with T3-4,N2-3 tumors, as well as in women aged less than 40 years, these observations need to be interpreted with caution in light of the small number of contributing studies, and absence of effect modification by stage, and age at diagnosis. There is hence a need, for future prospective clinical trials to assess the role of adjuvant radiotherapy in TNBC subgroups who currently fall outside the remit of conventional radiotherapy guidelines. In future work, the authors plan to conduct an individual participant data meta-analysis to improve understanding on the continued debate of adjuvant radiotherapy in TNBC.
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